-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Posts Q1 Loss $-0.29
7:09AM ET 5/05/2022 MT Newswires...
Quotes Snapshot > ALDX
Aldeyra Therapeutics Inc ALDX:NASDAQ
Last Price$2.46NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22
Today's Change-0.18(6.82%)
Bid (Size)$2.45 (10)
Ask (Size)$2.67 (12)
Day Low / High$2.45 - 2.62
Volume629.7 K
Read more news Recent News
Omega Therapeutics Hires Aldeyra Therapeutics Chief Financial Officer Joshua Reed for Same Role
7:49AM ET 4/29/2022 MT NewswiresOmega Therapeutics (OMGA) said Friday it appointed Joshua Reed as chief financial officer, effective May 23. Reed, who was most recently CFO of Aldeyra...
HC Wainwright Assumes Aldeyra Therapeutics at Buy with $15 Price Target
9:34AM ET 4/27/2022 MT NewswiresAldeyra Therapeutics (ALDX) has an average rating of buy and price targets ranging from $10 to $30, according to analysts polled by Capital IQ. (MT...
Aldeyra Therapeutics Completes Enrolling Patients in Dry Eye Disease Late-Stage Trial
9:37AM ET 4/05/2022 MT NewswiresAldeyra Therapeutics (ALDX) said Tuesday that it has finalized enrollment in the late-stage trial of 0.25% reproxalap ophthalmic solution in individuals...
View all Commentary and Analysis
Aldeyra Therapeutics Inc. (ALDX) CEO Dr. Todd Brady on Q1 2022 Results - Earnings Call Transcript
3:49PM ET 5/05/2022 Seeking AlphaAldeyra Therapeutics (ALDX) Investor Presentation -Slideshow
9:31AM ET 5/01/2022 Seeking AlphaAldeyra Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
9:31AM ET 4/06/2022 Seeking AlphaAldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2021 Results - Earnings Call Transcript
1:47PM ET 3/17/2022 Seeking AlphaCompany Profile
Business DescriptionAldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA. View company web site for more details
| Address | 131 Hartwell Avenue Lexington, Massachusetts 02421 |
| Phone | +1.781.761.4904 |
| Number of Employees | 19 |
| Recent SEC Filing | 05/18/2022 8-K |
| President, Chief Executive Officer & Director | Todd C. Brady |
| Chief Financial Officer, Treasurer & VP-Finance | Bruce Greenberg |
| Senior Vice President-Clinical Development | James A. Gow |
| Chief Development Officer | Stephen G. Machatha |
Company Highlights
| Price Open | $2.62 |
| Previous Close | $2.46 |
| 52 Week Range | $2.36 - 13.18 |
| Market Capitalization | $143.4 M |
| Shares Outstanding | 58.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.11 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -29.78% |
Analyst Ratings as of 04/26/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |